Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-Type TP53.
Mansoor N SalehManish R PatelTodd M BauerSanjay GoelGerald S FalchookGeoffrey I ShapiroKi Y ChungJeffrey R InfanteRobert M ConryGuilherme RabinowitsDavid S HongJudy S WangUlrich SteidlGurudatta NaikVincent GuerlavaisVojislav VukovicD Allen AnnisManuel AivadoFunda Meric-BernstamPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
ALRN-6924 was well tolerated and demonstrated anti-tumor activity.
Keyphrases